In recent trading session, Humacyte Inc (NASDAQ:HUMA) saw 1.24 million shares changing hands at last check today with its beta currently measuring 1.33. Company’s recent per share price level of $4.50 trading at -$0.18 or -3.84% at last check today assigns it a market valuation of $579.02M. That most recent trading price of HUMA’s stock is at a discount of -121.56% from its 52-week high price of $9.97 and is indicating a premium of 44.89% from its 52-week low price of $2.48. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 5.4 million shares which gives us an average trading volume of 4.77 million if we extend that period to 3-months.
For Humacyte Inc (HUMA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.29. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.26 in the current quarter.
Humacyte Inc (NASDAQ:HUMA) trade information
Upright in the red during last session for losing -3.84%, in the last five days HUMA remained trading in the red while hitting it’s week-highest on Tuesday, 01/07/25 when the stock touched $4.50 price level, adding 15.57% to its value on the day. Humacyte Inc’s shares saw a change of -10.89% in year-to-date performance and have moved -13.13% in past 5-day. Humacyte Inc (NASDAQ:HUMA) showed a performance of 6.76% in past 30-days. Number of shares sold short was 21.96 million shares which calculate 7.53 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 8 to the stock, which implies a rise of 43.75% to its recent value today. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 10. It follows that stock’s current price would drop -33.33% in reaching the projected high whereas dropping to the targeted low would mean a loss of -33.33% for stock’s current value.
Humacyte Inc (HUMA) estimates and forecasts
Statistics highlight that Humacyte Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -30.23% of value to its shares in past 6 months, showing an annual growth rate of -18.69% while that of industry is 16.50. Apart from that, the company came lowering its revenue forecast for fiscal year 2025.
And 4 analysts are in estimates of company making revenue of 1.78M in the next quarter.
Humacyte Inc (NASDAQ:HUMA)’s Major holders
Insiders are in possession of 26.87% of company’s total shares while institution are holding 30.04 percent of that, with stock having share float percentage of 41.09%. Investors also watch the number of corporate investors in a company very closely, which is 30.04% institutions for Humacyte Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at HUMA for having 7.14 million shares of worth $34.27 million. And as of 2024-06-30, it was holding 6.5961 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 4.73 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.3693 of outstanding shares, having a total worth of $22.7 million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Oct 31, 2024, the former fund manager was holding 2.66 shares of worth $11.92 million or 2.11% of the total outstanding shares. The later fund manager was in possession of 2.59 shares on Sep 30, 2024, making its stake of worth around $11.64 million in the company or a holder of 2.06% of company’s stock.
